Could a nordic diet help kids with Crohn's?
NCT ID NCT07334340
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a Nordic version of the Crohn's Disease Exclusion Diet in 30 children aged 6-18 with mild-to-severe Crohn's disease. The diet avoids inflammatory foods and gradually reintroduces unprocessed items over 20 weeks. Researchers will measure remission rates, diet adherence, and quality of life, comparing results to published data on the original diet.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nordic Crohn's Disease Exclusion Diet (N-CDED)
- What this could lead to
- If successful, this diet could offer a more personalized and easier-to-follow nutritional therapy for children with Crohn's disease, potentially reducing symptoms and the need for steroids.
- What could go wrong
- This is a small, early-stage study with only 30 participants and no control group, so results may not apply to all children. The diet is demanding and may be hard to stick with long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Children aged 6-18 years with recent (\<36 months) mild-to-severe CD diagnosis (defined as Paediatric Crohn's Disease Activity Index \[PCDAI\] 15-47.5) * Evidence of active inflammation (C-reactive protein \[CRP\] ≥ 0.5 mg/dL, erythrocyte sedimentation rate \[ESR\] ≥ 20 mm/h, and/or faecal calprotectin \[FCP\] ≥ 200 mg/g during screening) * Stable use of medication other than steroids. Exclusion Criteria: * Eating disorders, * Active extraintestinal manifestations * Use of systemic corticosteroids * Active perianal disease * Positive stool cultures for pathogens, parasites, or Clostridioides difficile * Fever \>38.3°C * Documented cow's milk protein allergy * Diabetes, celiac disease and/or psychosocial difficulties.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pediatric crohns disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Queen Silvia's Children's and Adolescent Hospital
Gothenburg, 41685, Sweden
-
Skaraborg Hospital Skövde, Pediatric Clinic
Skövde, 54949, Sweden
-
Skånes University Hospital
Malmö, Skåne County, 214 28, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.